Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.41 |
| ▸ | MIF | P14174 | 3/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15775795 | 0.86 | LPAR1 (0.40) | LPAR1MIFPSMB8CYP17A1SCN9A | |
| SCHEMBL15776043 | 0.86 | LPAR1 (0.46) | LPAR1PSMB8CYP17A1SCN9AHDAC3 | |
| SCHEMBL15775784 | 0.85 | EGLN2 (0.47) | LPAR1PSMB8CYP17A1 | |
| SCHEMBL15776816 | 0.85 | LPAR1 (0.45) | LPAR1PSMB8CYP17A1SCN9AHDAC3 | |
| SCHEMBL15776023 | 0.81 | PTPN1 (0.43) | LPAR1CYP17A1HDAC1 | |
| SCHEMBL15777090 | 0.80 | MAOB (0.43) | LPAR1HDAC1HDAC2 | |
| SCHEMBL15776778 | 0.80 | PTGS2 (0.42) | LPAR1PSMB8HDAC3HDAC1HDAC2 | |
| SCHEMBL15776042 | 0.80 | PTGS2 (0.42) | LPAR1PSMB8HDAC3HDAC1HDAC2 | |
| SCHEMBL15776537 | 0.80 | LPAR1 (0.45) | LPAR1CYP17A1 | |
| SCHEMBL15776040 | 0.79 | TRPV1 (0.38) | LPAR1PSMB8CYP17A1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290465-B2 | Substituted isoxazole amine compounds as inhibitors of SCD1 | HOFFMANN-LA ROCHE INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290465-B2 | Substituted isoxazole amine compounds as inhibitors of SCD1 | HOFFMANN-LA ROCHE INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290465-B2 | Substituted isoxazole amine compounds as inhibitors of SCD1 | HOFFMANN-LA ROCHE INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | HOFFMANN-LA ROCHE INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | HOFFMANN-LA ROCHE INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | HOFFMANN-LA ROCHE INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2925408-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014086667-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086667-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | SCD, CPT1A, SCD5 | LPAR1 1113/4885MIF 1973/4885PSMB8 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.